Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CVMNASDAQ:FRTXNYSE:JATTNASDAQ:LGVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCEL-SCI$0.24-6.8%$0.26$0.18▼$2.22$20.29M0.51.05 million shs1.28 million shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsJATTJATT Acquisition$1.24+2.5%$1.28$7.80▼$12.38$21.39MN/A41,322 shs290,396 shsLGVNLongeveron$1.35-6.3%$1.55$0.77▼$6.40$20.15M0.382.97 million shs63,062 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCEL-SCI+1.93%+5.16%-15.39%-37.70%-81.77%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%+0.54%+3.88%JATTJATT Acquisition+2.48%-13.89%+2.48%-17.88%-74.11%LGVNLongeveron-2.04%-0.69%-3.36%-8.28%+10.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVMCEL-SCIN/AN/AN/AN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ALGVNLongeveron3.1672 of 5 stars3.65.00.00.02.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVMCEL-SCI 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/ALGVNLongeveron 3.25Buy$8.67541.98% UpsideCurrent Analyst Ratings BreakdownLatest FRTX, CVM, LGVN, and JATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/3/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56JATTJATT AcquisitionN/AN/A$0.05 per share27.08($0.53) per shareN/ALGVNLongeveron$2.39M8.43N/AN/A$2.68 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVMCEL-SCI-$26.92M-$0.48N/AN/AN/AN/A-238.05%-104.65%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ALGVNLongeveron-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVMCEL-SCIN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVMCEL-SCI0.661.071.09FRTXFresh Tracks TherapeuticsN/AN/AN/AJATTJATT AcquisitionN/A0.150.15LGVNLongeveronN/A7.677.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVMCEL-SCI12.08%FRTXFresh Tracks Therapeutics25.04%JATTJATT Acquisition47.97%LGVNLongeveron10.01%Insider OwnershipCompanyInsider OwnershipCVMCEL-SCI9.93%FRTXFresh Tracks Therapeutics0.23%JATTJATT Acquisition20.00%LGVNLongeveron19.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVMCEL-SCI4384.12 million64.67 millionOptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableLGVNLongeveron2014.93 million12.00 millionNot OptionableFRTX, CVM, LGVN, and JATT HeadlinesRecent News About These CompaniesLongeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award RecipientMay 12 at 7:15 AM | globenewswire.comLongeveron (LGVN) to Release Quarterly Earnings on TuesdayMay 11 at 3:21 AM | americanbankingnews.comLongeveron Inc. (LGVN) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comLGVN Entering Crucial Period in Great ShapeMay 9, 2025 | msn.comRoth MKM Remains a Buy on Longeveron (LGVN)May 9, 2025 | theglobeandmail.comLongeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 9, 2025 | finance.yahoo.comLongeveron® Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | finance.yahoo.comLongeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025May 2, 2025 | globenewswire.comLongeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025April 23, 2025 | finance.yahoo.comLongeveron Inc. CEO Shares 2024 Progress and Strategic Goals for 2025 in Shareholder LetterApril 22, 2025 | quiverquant.comLongeveron Stock Short Interest Report | NASDAQ:LGVN | BenzingaApril 18, 2025 | benzinga.comLGVN Announces Positive Alzheimer’s NewsMarch 20, 2025 | msn.comLongeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s DiseaseMarch 20, 2025 | finance.yahoo.comLongeveron (LGVN) Receives a Buy from Roth MKMMarch 20, 2025 | markets.businessinsider.comRoth MKM Keeps Their Buy Rating on Longeveron (LGVN)March 12, 2025 | markets.businessinsider.comLongeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's DiseaseMarch 11, 2025 | finanznachrichten.deLongeveron announces publication of results of Phase 2a trial of Lomecel-BMarch 11, 2025 | markets.businessinsider.comLongeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease TreatmentMarch 11, 2025 | quiverquant.comLongeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's DiseaseMarch 11, 2025 | globenewswire.comLongeveron® to Present at the 37th Annual Roth ConferenceMarch 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFRTX, CVM, LGVN, and JATT Company DescriptionsCEL-SCI NYSE:CVM$0.24 -0.02 (-6.84%) As of 04:00 PM EasternCEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.JATT Acquisition NYSE:JATT$1.24 +0.03 (+2.48%) As of 05/12/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Longeveron NASDAQ:LGVN$1.35 -0.09 (-6.25%) As of 04:00 PM EasternLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
